Diamyd Medical invests in broad international patent protection for Diamyd® and new study drug has been produced

Diamyd Medical today announced in its second quarterly report for the fiscal year 2016/2017 that the patent application involving intralymphatic administration of antigen is in international investigation phase in several countries including the United States, Europe, Japan and China. Granted claims provide protection that extends to 2035. The Company also informs that a successful production of new Diamyd® has been carried out by the new manufacturer and study drugs lasts until 2021. Production of a proprietary GABA study drug proceeds per plan and has entered formulation development and a